Persistent Hiccups After Switching from Zuclopenthixol to Aripiprazole

Duvarci, İbrahim; Yılmaz, Mustafa

doi:10.5455/bcp.20120419125722

Cited by 6 publications

(5 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, olanzapine seems to be a successful antipsychotic agent in the context of singultus suppression ( Alderfer and Arciniegas, 2006 ; Rizzo et al, 2014 ). There is an abundance of reports on hiccups associated with aripiprazole treatment ( Behere et al, 2007 ; Ginsberg, 2007 ; Ray et al, 2009 ; De Filippis et al, 2015 ; Sakalli Kani et al, 2015 ; Caloro et al, 2016 ; Kutuk et al, 2016 ) and on persistent hiccups associated with switching antipsychotic treatment from risperidone to aripiprazole ( Yeh, 2011 ), from a typical antipsychotic drug of the thioxanthene class to aripiprazole ( Duvarci and Yilmaz, 2013 ), and from olanzapine to aripiprazole ( Hori and Nakamura, 2014 ). In a patient treated with aripiprazole, singultus persisted, despite trials of metoclopramide and chlorpromazine; remission of hiccups occurred after discontinuation of aripiprazole ( Silverman et al, 2014 ).…”

Section: Purpose Of the Workmentioning

confidence: 99%

The Role of Serotonin in Singultus: A Review

Petroianu

Lorke

2020

Front. Neurosci.

View full text Add to dashboard Cite

The use of dopamine receptor blockers for chronic singultus treatment is basedat least partially-on circular thinking: chlorpromazine is FDA-approved for hiccups, chlorpromazine is a neuroleptic, neuroleptics are dopamine receptor blockers, and therefore hiccup is due to dopaminergic dysfunction. Chlorpromazine interacts with high affinity with a multitude of receptors and ion channels. This promiscuity is the basis for many of the therapeutic effects and adverse drug reactions of this drug. While an involvement of dopamine is certain, it is by no means clear that dopaminergic dysfunction is the hallmark of singultus. The common denominator of most remedies for transient hiccup is their ability to activate the vagus nerve. Both afferent and efferent vagal activity and the central integration of the Xth cranial nerve function are modulated, inter alia, via serotonergic mechanisms; beneficial (therapeutic) effects for hiccup are to be expected from serotonin (5-HT) receptor subtype ligands that enhance vagal activity. Taken together, it appears that the ability to increase vagus output is mainly associated with 5-HT 1A , 5-HT 3 , and 5-HT 7 agonists and with 5-HT 2C antagonists. The plausibility of the serotonergic singultus hypothesis is examined against available pharmacokinetic, pharmacodynamic, and clinical data for a number of drugs.

show abstract

Section: Purpose Of the Workmentioning

confidence: 99%

The Role of Serotonin in Singultus: A Review

Petroianu

Lorke

2020

Front. Neurosci.

View full text Add to dashboard Cite

show abstract

“…The symptom subsided 4 days after aripiprazole discontinuation. 36 The only woman who developed aripiprazole-related hiccup after challenge and rechallenge without taking concomitant BDZs did so after switching from olanzapine; hiccup disappeared when she was further switched to 9-hydroxyrisperidone. 37 Other 2 cases of aripiprazole-related hiccups in young men developed while the patients were also on the BDZs clonazepam 38 or lorazepam 39 ; the second case was apparently dose related.…”

Section: Discussionmentioning

confidence: 98%

Development of Hiccup in Male Patients Hospitalized in a Psychiatric Ward

Caloro

Pucci

Calabrò

et al. 2016

Clinical Neuropharmacology

View full text Add to dashboard Cite

show abstract

“…However, other additional risk factors have been hypothesized to explain its occurrence. For instance, the association with hyponatremia (Ginsberg 2007 In particular, switching from a D2 high potency blocker to aripiprazole seems to increase the risk of hiccup occurrence, although other mechanisms, involving gabaergic and serotoninergic transmission, are presumably implicated (Yeh 2011, Duvarci & Yilmaz 2013. The importance of the interaction between aripiprazole and benzodiazepine in hiccup occurrence needs to be taken into consideration as well.…”

Section: Discussionmentioning

confidence: 99%

Aripiprazole-Induced Persistent Hiccup: A Case Report and Review of the Literature

et al. 2019

View full text Add to dashboard Cite

Aripiprazole is an interesting psychoactive compound acting as a dopamine D2 partial agonist, serotonin 5-HT(1A) partial agonist and serotonin 5-HT(2A) antagonist. Aripiprazole possesses a well-documented efficacy in the treatment of both positive and negative psychotic symptoms. However, this medication may be rarely associated with the onset of hiccup. Here, we present the case of aripiprazole-induced hiccup in a young inpatient at his first psychiatric admission together with a review of the current literature about this topic. The possible etiology underlying the emergence of hiccups together with the clinical implications of this adverse event are discussed.

show abstract

Persistent Hiccups After Switching from Zuclopenthixol to Aripiprazole

Cited by 6 publications

References 6 publications

The Role of Serotonin in Singultus: A Review

The Role of Serotonin in Singultus: A Review

Development of Hiccup in Male Patients Hospitalized in a Psychiatric Ward

Aripiprazole-Induced Persistent Hiccup: A Case Report and Review of the Literature

Contact Info

Product

Resources

About